Senate LDA lobbying filing
ELI LILLY AND COMPANY FKA LILLY USA, LLC
Reported income
$50.0K
Reported expenses
not reported
Tracked program mentions2
Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the…
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the…
Lobbying activities3
Budget/AppropriationsBUD
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Health IssuesHCR
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Medicare/MedicaidMMM
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Lobbyists5
- CYNTHIA BROWN
- DERRICK WHITE
- ELIZABETH GREER
- KRISTINA DUNKLIN
- MICHAEL WILLIAMS
Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.